title: The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis.
abstract: BACKGROUND
  Glial fibrillary acidic protein (GFAP) is a specific intermediate filament of the cytoskeleton of the astrocyte and may be used as a specific marker for astrocytic damage. It is detectable in the cerebrospinal fluid following a relapse caused by Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) spectrum disease. Higher levels are found following an NMO-related relapse. It is not known if GFAP is also detectable in the serum following such relapses. In particular, it is not known if lesions limited to the optic nerve release GFAP in sufficient quantities to be detectable within the serum. The aim of this study was to ascertain the extent to which serum GFAP levels can distinguish between an episode of optic neuritis (ON) related to NMO spectrum disease and ON from other causes.
  
  
  RESULTS
  Out of 150 patients consecutively presenting to our eye hospital over the period March 2009 until July 2010, we were able to collect a serum sample from 12 patients who had presented with MS-related ON and from 10 patients who had presented with NMO spectrum disease-related ON. We also identified 8 patients with recurrent isolated ON and 8 patients with a corticosteroid-dependent optic neuropathy in the absence of any identified aetiology. GFAP was detectable in the serum of all but three patients (two patients with MS-related ON and one with recurrent optic neuritis). The median serum GFAP level in the patient group with NMO spectrum disease was 4.63 pg/mL whereas in all other cases combined together, this was 2.14 pg/mL. The difference was statistically significant (P = 0.01). A similar statistically significant difference was found when cases with pathology limited to the optic nerve were compared (P = 0.03).
  
  
  CONCLUSIONS
  Glial pathology in NMO related optic neuritis is reflected in elevated serum GFAP levels independently of whether or not there is extra-optic nerve disease.
authors.affiliation: The National Hospital for Neurology and Neurosurgery, London, United Kingdom. m.storoni@doctors.net.uk
authors.forename: Mithu
authors.initials: M
authors.lastname: Storoni
authors.forename: Axel
authors.initials: A
authors.lastname: Petzold
authors.forename: Gordon T
authors.initials: GT
authors.lastname: Plant
mesh_terms: D000328:Adult; D051401:Aquaporin 4 / Q000378:metabolism; D003937:Diagnosis, Differential; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000097:blood*; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology; D009471:Neuromyelitis Optica / Q000097:blood* / Q000175:diagnosis* / Q000503:physiopathology; D009900:Optic Nerve / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D014785:Vision, Ocular
chemical_list: D051401:Aquaporin 4; D005904:Glial Fibrillary Acidic Protein